create digital currency Knowledge graph

Analysis and interpretation of artificial intelligence, semiconductor, medicine and Hong Kong stock technology!Analysis and interpretation of artificial intelligence, semiconductor, medicine and Hong Kong stock technology!

4. The Hang Seng Science and Technology Index of Hong Kong stocks rose 4.24% to 4,854.34 points after rising 4.30% yesterday. However, there was a wave of diving soon, and the plate was close to the green plate, which was too ugly to eat. In addition, it is widely expected that the European Central Bank will cut interest rates by 50 basis points on December 12, which will make the US dollar index rise again, thus accelerating the outflow of funds from Hong Kong stocks. Therefore, in the face of this uncertainty, part of the profit will be stopped first.Analysis and interpretation of artificial intelligence, semiconductor, medicine and Hong Kong stock technology!

4. The Hang Seng Science and Technology Index of Hong Kong stocks rose 4.24% to 4,854.34 points after rising 4.30% yesterday. However, there was a wave of diving soon, and the plate was close to the green plate, which was too ugly to eat. In addition, it is widely expected that the European Central Bank will cut interest rates by 50 basis points on December 12, which will make the US dollar index rise again, thus accelerating the outflow of funds from Hong Kong stocks. Therefore, in the face of this uncertainty, part of the profit will be stopped first.2. In the case of a breakthrough in the substitution of domestic chips, our side suddenly attacked NVIDIA last night, causing it to drop by 2.55%, which obviously stimulated the market sentiment, making the semiconductor sector change yesterday's decline, ushered in a retaliatory rebound, and formed a strong "Yang Bao Yin" form. However, while rejoicing, don't underestimate the determination of the United States to counter it.3. Catalyzed by the deregulation of innovative drugs by the Biosafety Law of the United States, the pharmaceutical sector has gone out of a continuous rebound trend, especially the Pharmaceutical Department has ushered in some performance opportunities. However, before the revenue is gradually transferred from the US market, it will be easily grasped by others.